Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Modeling alveolar barrier disruption in vitro for sepsis-induced ARDS preclinical studies

Nuria Roldan, Giulia Raggi, Kleanthis Fytianos, Jessica Petracca, Janick Stucki, Fabian Käsermann, Nina Hobi
European Respiratory Journal 2020 56: 3346; DOI: 10.1183/13993003.congress-2020.3346
Nuria Roldan
1AlveoliX AG, Swiss Organs-on-Chip Innovation, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nuria.roldan@alveolix.com
Giulia Raggi
1AlveoliX AG, Swiss Organs-on-Chip Innovation, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kleanthis Fytianos
2CSL Behring, Research, CSL Biologics Research Center, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Petracca
2CSL Behring, Research, CSL Biologics Research Center, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janick Stucki
1AlveoliX AG, Swiss Organs-on-Chip Innovation, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabian Käsermann
2CSL Behring, Research, CSL Biologics Research Center, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nina Hobi
1AlveoliX AG, Swiss Organs-on-Chip Innovation, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Disruption of the alveolar barrier is one of the main features of Acute Respiratory Distress Syndrome (ARDS), a devastating disease with no pharmacological treatments available at present. Sepsis is also a common risk factor for the development of ARDS, associated with 30% of the cases. During sepsis, hemolysis takes place, leading to the release of haemoglobin and heme in the bloodstream, which have been shown to contritube to cytotoxicity and inflammation. We aimed to develop an in vitro alveolar barrier disruption model that mimics some of the sepsis-induced ARDS main characteristics. For this purpose, epithelial and endothelial co-cultures on an in vitro micro-physiological system (MPS) were exposed to lipopolysaccharide (LPS) and hemin (i.e. the oxidized form of heme) and the effects on barrier disruption and inflammation were investigated.

Hemin led to barrier disruption (>90% transbarrier resistance reduction) regardless of the presence of LPS or Peripheral Blood Mononuclear Cells (PBMCs). This was accompanied by an increase in the gene expression of Heme Oxygenase – 1 (> 80-fold) and endothelial damage, indicated by disruption of the cell layers. LPS treatment increased pro-inflammatory cytokine secretion (IL-8, TNF-α and IL1-β) in PBMCs. Hemin combined with LPS also induced pro-inflammatory responses but to a lower extent.

In conclusion, our human alveolar barrier disruption model appears to be appropriate to study heme-induced toxicity and inflammation and thus may be a relevant tool for preclinical drug testing.

  • Inflammation
  • Experimental approaches
  • Epithelial cell

Footnotes

Cite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 3346.

This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2020
Previous
Back to top
Vol 56 Issue suppl 64 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Modeling alveolar barrier disruption in vitro for sepsis-induced ARDS preclinical studies
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Modeling alveolar barrier disruption in vitro for sepsis-induced ARDS preclinical studies
Nuria Roldan, Giulia Raggi, Kleanthis Fytianos, Jessica Petracca, Janick Stucki, Fabian Käsermann, Nina Hobi
European Respiratory Journal Sep 2020, 56 (suppl 64) 3346; DOI: 10.1183/13993003.congress-2020.3346

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Modeling alveolar barrier disruption in vitro for sepsis-induced ARDS preclinical studies
Nuria Roldan, Giulia Raggi, Kleanthis Fytianos, Jessica Petracca, Janick Stucki, Fabian Käsermann, Nina Hobi
European Respiratory Journal Sep 2020, 56 (suppl 64) 3346; DOI: 10.1183/13993003.congress-2020.3346
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Eosinophils and COVID-19 prognosis
  • Tight junction molecules are unresponsive in the epithelium of COPD patients during RV infection
  • LSC - 2021 - Submicroscopic changes of type I alveolocytes in the early stages of experimental diabetes mellitus
Show more Mechanisms of lung injury and repair

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society